[{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV channel-alpha-subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Regenexx \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Pregene"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/ Bone Therapeutics"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Merger","leadProduct":"Beta-tricalcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"}]
Find Drugs for Orthopedics/Orthopedic Surgery in Phase II Clinical Development in UNITED STATES
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
